ABCB1 gene variants influence tolerance to selective serotonin reuptake inhibitors in a large sample of Dutch cases with major depressive disorder

[1]  R. Altman,et al.  Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein). , 2011, Pharmacogenetics and genomics.

[2]  Y. Chiu,et al.  ABCB1 gene polymorphisms are associated with the severity of major depressive disorder and its response to escitalopram treatment , 2010, Pharmacogenetics and genomics.

[3]  L. Lazzeroni,et al.  ABCB1 (MDR1) polymorphisms and antidepressant response in geriatric depression , 2010, Pharmacogenetics and genomics.

[4]  R. Perlis,et al.  Failure to Replicate Genetic Associations with Antidepressant Treatment Response in Duloxetine-Treated Patients , 2010, Biological Psychiatry.

[5]  J. Licinio,et al.  Sequence variations of ABCB1, SLC6A2, SLC6A3, SLC6A4, CREB1, CRHR1 and NTRK2: association with major depression and antidepressant response in Mexican-Americans , 2009, Molecular Psychiatry.

[6]  Marcella Rietschel,et al.  Adverse reactions to antidepressants. , 2009, The British journal of psychiatry : the journal of mental science.

[7]  N. Wray,et al.  Genomewide Association for Major Depressive Disorder: A possible role for the presynaptic protein Piccolo , 2008, Molecular Psychiatry.

[8]  Jonathan Marchini,et al.  Comparing algorithms for genotype imputation. , 2008, American journal of human genetics.

[9]  P. Cuijpers,et al.  The Netherlands Study of Depression and Anxiety (NESDA): rationale, objectives and methods , 2008, International journal of methods in psychiatric research.

[10]  N. Božina,et al.  MDR1 gene polymorphism: therapeutic response to paroxetine among patients with major depression , 2008, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[11]  G. Jenkins,et al.  Pharmacokinetic Genes Do Not Influence Response or Tolerance to Citalopram in the STAR*D Sample , 2008, PloS one.

[12]  A. Serretti,et al.  ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder , 2008, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[13]  J. Donovan,et al.  Sertraline and its metabolite desmethylsertraline, but not bupropion or its three major metabolites, have high affinity for P-glycoprotein. , 2008, Biological & pharmaceutical bulletin.

[14]  F. Holsboer,et al.  Polymorphisms in the Drug Transporter Gene ABCB1 Predict Antidepressant Treatment Response in Depression , 2008, Neuron.

[15]  M. Pirmohamed,et al.  ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research , 2007, The Pharmacogenomics Journal.

[16]  T. Asada,et al.  MDR1 gene polymorphism in Japanese patients with schizophrenia and mood disorders including depression. , 2006, Biological & pharmaceutical bulletin.

[17]  S. Spinler,et al.  Role of P‐glycoprotein in Statin Drug Interactions , 2006, Pharmacotherapy.

[18]  M. Ott,et al.  Inhibition of P-Glycoprotein Function by Several Antidepressants may not Contribute to Clinical Efficacy , 2005, Pharmacopsychiatry.

[19]  Wolfgang Löscher,et al.  Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases , 2005, Progress in Neurobiology.

[20]  Xi Chen,et al.  THE IMPACT OF P-GLYCOPROTEIN ON THE DISPOSITION OF DRUGS TARGETED FOR INDICATIONS OF THE CENTRAL NERVOUS SYSTEM: EVALUATION USING THE MDR1A/1B KNOCKOUT MOUSE MODEL , 2005, Drug Metabolism and Disposition.

[21]  R. Ho,et al.  (Section A: Molecular, Structural, and Cellular Biology of Drug Transporters) The Role of MDR1 Genetic Polymorphisms in Interindividual Variability in P-glycoprotein Expression and Function , 2004 .

[22]  F. Holsboer,et al.  Differential enhancement of antidepressant penetration into the brain in mice with abcb1ab (mdr1ab) P-Glycoprotein gene disruption , 2003, Biological Psychiatry.

[23]  W. Haefeli,et al.  Inhibition of P-Glycoprotein by Newer Antidepressants , 2003, Journal of Pharmacology and Experimental Therapeutics.

[24]  R. Weizman,et al.  Age-related differences in the side effect profile of citalopram , 2002, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[25]  Peter H. Westfall,et al.  Testing Association of Statistically Inferred Haplotypes with Discrete and Continuous Traits in Samples of Unrelated Individuals , 2002, Human Heredity.

[26]  D. Greenblatt,et al.  P‐glycoprotein Interactions of Nefazodone and Trazodone in Cell Culture , 2001, Journal of clinical pharmacology.

[27]  K. Brouwer,et al.  Pharmacokinetic and Pharmacodynamic Implications of P‐glycoprotein Modulation , 2001, Pharmacotherapy.

[28]  P. Donnelly,et al.  A new statistical method for haplotype reconstruction from population data. , 2001, American journal of human genetics.

[29]  F. Holsboer,et al.  Penetration of Amitriptyline, but Not of Fluoxetine, into Brain is Enhanced in Mice with Blood-Brain Barrier Deficiency Due to Mdr1a P-Glycoprotein Gene Disruption , 2000, Neuropsychopharmacology.

[30]  J. Molnár,et al.  Anti-psychotic drugs reverse multidrug resistance of tumor cell lines and human AML cells ex-vivo. , 1999, Cancer letters.

[31]  U. Ahlfors,et al.  The UKU side effect rating scale: A new comprehensive rating scale for psychotropic drugs and a cross‐sectional study of side effects in neuroleptic‐treated patients , 1987, Acta psychiatrica Scandinavica. Supplementum.

[32]  N. Cutler,et al.  The impact of gender on antidepressants. , 2011, Current topics in behavioral neurosciences.

[33]  R. Bendayan,et al.  Molecular and functional characterization of P-glycoprotein in vitro. , 2011, Methods in molecular biology.

[34]  W. Haefeli,et al.  Impact of ATP-binding cassette transporters on human immunodeficiency virus therapy. , 2010, International review of cell and molecular biology.

[35]  P. Sullivan,et al.  Genome-wide association of major depression: description of samples for the GAIN Major Depressive Disorder Study: NTR and NESDA biobank projects , 2008, European Journal of Human Genetics.

[36]  R. Ho,et al.  The role of MDR1 genetic polymorphisms in interindividual variability in P-glycoprotein expression and function. , 2004, Current drug metabolism.

[37]  E. Mundo,et al.  Investigation of polymorphism in the MDR1 gene and antidepressant-induced mania , 2003, The Pharmacogenomics Journal.

[38]  P. Joyce,et al.  A common P-glycoprotein polymorphism is associated with nortriptyline-induced postural hypotension in patients treated for major depression , 2002, The Pharmacogenomics Journal.

[39]  M. Stephens,et al.  Accounting for Decay of Linkage Disequilibrium in Haplotype Inference and Missing-data Imputation , 2022 .